IL307980A - A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female - Google Patents

A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female

Info

Publication number
IL307980A
IL307980A IL307980A IL30798023A IL307980A IL 307980 A IL307980 A IL 307980A IL 307980 A IL307980 A IL 307980A IL 30798023 A IL30798023 A IL 30798023A IL 307980 A IL307980 A IL 307980A
Authority
IL
Israel
Prior art keywords
depressive disorder
major depressive
neuroactive steroid
postpartum depression
lactating female
Prior art date
Application number
IL307980A
Other languages
English (en)
Hebrew (he)
Inventor
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Handan Gunduz-Bruce
Amy E Bullock
Jeffrey A Wald
Original Assignee
Sage Therapeutics Inc
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Gunduz Bruce Handan
Amy E Bullock
Jeffrey A Wald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc, Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Gunduz Bruce Handan, Amy E Bullock, Jeffrey A Wald filed Critical Sage Therapeutics Inc
Publication of IL307980A publication Critical patent/IL307980A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL307980A 2021-04-29 2022-04-29 A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female IL307980A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181807P 2021-04-29 2021-04-29
PCT/US2022/026908 WO2022232494A1 (en) 2021-04-29 2022-04-29 Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female

Publications (1)

Publication Number Publication Date
IL307980A true IL307980A (en) 2023-12-01

Family

ID=81748326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307980A IL307980A (en) 2021-04-29 2022-04-29 A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female

Country Status (9)

Country Link
US (1) US20240216396A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329769A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515830A (cg-RX-API-DMAC7.html)
CN (1) CN117580580A (cg-RX-API-DMAC7.html)
AU (1) AU2022267304A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217866A1 (cg-RX-API-DMAC7.html)
IL (1) IL307980A (cg-RX-API-DMAC7.html)
MX (1) MX2023012728A (cg-RX-API-DMAC7.html)
WO (1) WO2022232494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ,インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Also Published As

Publication number Publication date
EP4329769A1 (en) 2024-03-06
CN117580580A (zh) 2024-02-20
US20240216396A1 (en) 2024-07-04
AU2022267304A1 (en) 2023-11-02
MX2023012728A (es) 2023-11-08
JP2024515830A (ja) 2024-04-10
WO2022232494A1 (en) 2022-11-03
CA3217866A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
GB2595517B (en) Methods and apparatuses for synchronization in a multi-AP coordination
PL3908270T3 (pl) Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego
IL280526A (en) Bracelets targeting the muscle and their use for the treatment of muscle atrophy
IL281816A (en) Medical device and method for performing a surgical operation on the body
IL292040A (en) Instruments and methods for modulating the activity of the immune system in a cancer patient and cancer treatment
SG11202002743TA (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
IL307464A (en) OFATUMUMAB for the treatment of multiple sclerosis in Asian patients
HK40109202A (en) Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
IL317048A (en) Peptides and methods for use in the treatment of pain
GB202214972D0 (en) Products and methods for use in treating NDP-related diseases
GB202205134D0 (en) Modeling devices used in guided bone and tissue regeneration
IL317438A (en) FITUSIRAN for the treatment of hemophilia A and B in pediatric patients
SG11202008914WA (en) A platform and system for use in therapeutic procedures
GB2616093B (en) Methods and apparatuses for synchronization in a multi-AP coordination
IL298503B1 (en) Immune modulator complex and its uses for treatment
GB202020625D0 (en) Devices and methods for delivering non-coplanar radiotherapy
IL315174A (en) Abiraterone decanoate drug metrics and treatment use
SI3906970T1 (sl) Parapoksvirus za kondicioniranje in zdravljenje koronavirusnih okužb
IL315893A (en) 5-MEO-DMT for use in the treatment of postpartum depression
GB202311356D0 (en) Methods and devices for event coordination in multi-ap operation
HK40085135A (en) C-type natriuretic peptides and methods thereof in treating cancer
GB202108437D0 (en) Apparatus for improving hydration and/or reducing particle size of a product and a method of use thereof
ZA202107319B (en) Method for preventing and treating scab disease
HK40118427A (en) Peptides and methods for use in treating pain
GB2579704B (en) Conditioning system and method for a use in a controlled atmosphere workstation